礼来公司的唯择(阿贝西利)通过两年治疗提高了激素受体阳性(HR+)、人表皮生长因子受体2阴性(HER2-)高危早期乳腺癌患者的总生存期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.